IC-MPGN

10 registered clinical trials studyying IC-MPGN — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Chinese Adults With Kidney Disease NCT07522099	ADARx Pharmaceuticals, Inc.	Phase 2
Recruiting	Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease NCT06989359	ADARx Pharmaceuticals, Inc.	Phase 2
Not Yet Recruiting	A Study of SGB-9768 in Patients with Complement-mediated Kidney Diseases NCT06786338	Suzhou Sanegene Bio Inc.	Phase 2
Recruiting	Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN NCT05755386	Novartis Pharmaceuticals	Phase 3
Active Not Recruiting	An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Peg NCT05809531	Apellis Pharmaceuticals, Inc.	Phase 3
Completed	Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immun NCT05067127	Apellis Pharmaceuticals, Inc.	Phase 3
Active Not Recruiting	Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN NCT04572854	Apellis Pharmaceuticals, Inc.	Phase 2
Completed	Non-contrast Enhanced MRI in Patients With C3 Glomerulopathy (C3G) or Immune-complex Membranoproliferative Glo NCT03723512	Mario Negri Institute for Pharmacological Research	N/A
Terminated	A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471 NCT03459443	Alexion Pharmaceuticals, Inc.	Phase 2
Approved For Marketing	C3G/Primary IC-MPGN EAP NCT04729062	Apellis Pharmaceuticals, Inc.	—